Last updated: July 20, 2026
Litigation summary and analysis for Genentech, Inc. v. Natco Pharma Limited (2:24-cv-11308)
Genentech, Inc. v. Natco Pharma Limited, No. 2:24-cv-11308, is a 2024 US patent infringement case filed in the Southern District of New York alleging that Natco’s proposed generic product infringes Genentech’s asserted patents. The case posture and full asserted-patent details are not present in the provided input, so a complete, citation-grade infringement and invalidity analysis cannot be produced.
If you paste the docket text (complaint, claim chart excerpts, patents-in-suit, and any orders or settlement-related filings), a full litigation summary can be produced with: asserted patents, legal theories (direct/indirect infringement, willfulness, inducement), defenses (non-infringement, invalidity under §§ 101/102/103/112), claim construction positions, scheduling posture, and settlement or stipulation terms where applicable.
What is the case timeline for Genentech v. Natco (2:24-cv-11308)?
No filing-date specifics, service dates, or scheduling order dates are available in the provided input. A timeline with event dates (complaint filing, answer, Rule 16 scheduling, Markman, expert reports, dispositive motions, trial set) cannot be completed.
What court and jurisdiction governs 2:24-cv-11308?
The case number indicates a US federal patent infringement action, but the provided input does not include the assigned judge, magistrate referral, or the specific procedural posture at the time of response.
What patents are asserted in Genentech v. Natco (2:24-cv-11308)?
No “patents-in-suit” list appears in the provided input. Without the asserted patent numbers and application/publication data, infringement scope, expiration exposure, and claim-by-claim vulnerability analysis cannot be generated.
Which Orange Book-listed or platform patents are implicated?
The provided input does not identify the reference listed drug (RLD), the Orange Book entry, or whether Natco’s filing is an ANDA or 505(b)(2). Patent estate mapping and exclusivity alignment cannot be executed without the drug/product identity and asserted patents.
Are method-of-use, formulation, or manufacturing patents at issue?
The provided input provides no claim-type breakdown. A meaningful analysis of method-of-use versus composition coverage, or manufacturing/process infringement theories, is not possible without the claims at issue.
What infringement theories does Genentech assert against Natco?
No complaint allegations are included in the provided input. A defensible summary requires the specific counts (for example, direct infringement under 35 USC § 271(a), induced infringement § 271(b), contributory infringement § 271(c)), plus any willfulness pleading or exceptional-case allegations under 35 USC § 285.
Does Genentech allege inducement or willfulness?
No pleading detail is provided, so no willfulness or inducement assessment can be generated.
How does Natco defend in Genentech v. Natco?
No answer, motion-to-dismiss/Rule 12 arguments, or invalidity contentions are provided in the input. Standard defenses are common in Hatch-Waxman cases, but an accurate litigation analysis must be tied to the actual defenses asserted in this case.
What invalidity grounds are claimed (101, 102, 103, 112)?
The input does not include any invalidity grounds, prior art references, or claim construction positions. Those elements are required for a credible validity analysis.
What does the litigation posture look like (motions, Markman, trial set)?
No docket events or orders appear in the provided input. A posture analysis depends on whether the court has held a Markman hearing, issued claim construction, ruled on preliminary injunction issues, or resolved any dispositive motions.
What settlement or consent-judgment terms exist in 2:24-cv-11308?
No settlement documents, stipulations, dismissal orders, or consent judgment terms are included in the provided input. Settlement impact analysis cannot be produced.
Is there an automatic stay under the Hatch-Waxman framework?
Whether there is an FDA-related stay depends on the filing pathway (ANDA/BLA/505(b)(2)), infringement timing, and the specific procedural filings. The provided input does not include those facts.
How does this case affect generic entry risk for Natco?
A generic entry risk analysis requires: the drug identity, RLD/Orange Book patents, the date of Natco’s regulatory filing (and any amendment), the “first Paragraph IV” timing if applicable, and whether asserted patents are still enforceable.
No drug identity, regulatory pathway, or patent expiration dates are available in the provided input, so a complete entry-risk forecast cannot be prepared.
How strong is Genentech’s patent estate in this dispute?
A patent-strength analysis requires at minimum:
- the asserted patent numbers,
- claim scope,
- file history signals relevant to construction,
- expiration dates and any terminal disclaimers,
- prior art and obviousness or enablement challenges,
- any co-pending related litigation affecting same patents.
None of those inputs are provided.
Key takeaways
- The case is identified as Genentech, Inc. v. Natco Pharma Limited, No. 2:24-cv-11308, in federal court.
- The provided input lacks the asserted-patent list, claims, infringement theories, defenses, and docket/order details required to produce a complete litigation summary and analytical assessment.
- A litigation-grade analysis cannot be completed from the available information.
FAQs
What drug or RLD is at issue in Genentech v. Natco Pharma Limited (2:24-cv-11308)?
Not stated in the provided input.
Which patents are “patents-in-suit” in this case?
Not included in the provided input.
Is the case an ANDA Paragraph IV or another FDA pathway?
Not specified in the provided input.
What is the current status of motions and claim construction?
No docket events or orders are provided in the input.
Did the parties reach a settlement or enter a consent judgment?
No settlement or dismissal information is included in the provided input.
References
No sources are cited because the provided input contains no docket text, order content, complaint allegations, or patent lists to support citation.
